Results 61 to 70 of about 284,151 (314)

The distinctive nature of adenocarcinoma of the lung

OncoTargets and Therapy, 2015
In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib and ceritinib are two new tyrosine kinase inhibitors ...
openaire   +6 more sources

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

Rab3B enhances the stabilization of DDX6 to promote lung adenocarcinoma aggressiveness

Molecular Medicine
Background Liver kinase B1 (LKB1) is frequently mutated in lung adenocarcinoma, and its loss contributes to tumor progression. Methods To identify LKB1 downstream genes that promote lung adenocarcinoma aggressiveness, we performed bioinformatical ...
Guodong Yao, Shan Yu, Feng Hou, Zunyu Xiao, Guangqi Li, Xiaobin Ji, Jigang Wang   +6 more
doaj   +1 more source

PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway

Molecular Cancer, 2017
Background Protein regulator of cytokinesis-1 (PRC1) belongs to the microtubule-associated proteins (MAPs) family, and is involved in cytokinesis.
Ping Zhan, Bin Zhang, Guang-min Xi, Ying Wu, Hong-bing Liu, Ya-fang Liu, Wu-jian Xu, Qing-qing Zhu, Feng Cai, Ze-jun Zhou, Ying-ying Miu, Xiao-xia Wang, Jia-jia Jin, Qian Li, Li-ping Qian, Tang-feng Lv, Yong Song   +16 more
doaj   +1 more source

Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis

Scientific Reports, 2021
Genetic alterations underlying the development of lung cancer in individuals with idiopathic pulmonary fibrosis (IPF) have remained unclear. To explore whether genetic alterations in IPF tissue contribute to the development of IPF-associated lung cancer,
Yasuto Yoneshima, Eiji Iwama, Shingo Matsumoto, Taichi Matsubara, Testuzo Tagawa, Keiichi Ota, Kentaro Tanaka, Mitsuhiro Takenoyama, Tatsuro Okamoto, Koichi Goto, Masaki Mori, Isamu Okamoto   +11 more
doaj   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Widespread rash in lung adenocarcinoma

ESMO Open, 2018
A 68-year-old man is being treated with cisplatin-pemetrexed in the first line for bone metastatic lung adenocarcinoma. There is partial response and very good tolerance with no grade 3–4 toxicities. After six cycles of doublet therapy, the patient follows on pemetrexed maintenance. Six months later, he develops a hot and itchy rash with …
José Miguel Jurado, Fernando Gálvez-Montosa, Francisco Almazan   +2 more
openaire   +2 more sources

Molecular biomarkers for lung adenocarcinoma [PDF]

European Respiratory Journal, 2017
The identification of oncogenic driver alterations that underlie sensitivity to small inhibitors has led to growing interest in identifying additional targetable oncogenes in nonsmall cell lung cancer. Although the therapeutic impact of the discovery of these alterations has now been widely demonstrated, the epidemiological data associated with each of
Anne Pradines, Julien Mazieres, Olivier Calvayrac, Elvire Pons, Nicolas Guibert, Nicolas Guibert   +5 more
openaire   +3 more sources

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source

Endoglin mediates the tumor‐ and metastasis‐promoting traits of stromal myofibroblasts in human breast carcinomas

Molecular Oncology, EarlyView.
Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo, Yoshihiro Mezawa, Zixu Wang, Ahmet Acar, Yasuhiko Ito, Atsushi Takano, Yohei Miyagi, Tomoyuki Yokose, Toshinari Yamashita, Yataro Daigo, Takuya Shirakihara, Akira Orimo   +11 more
wiley   +1 more source